Individualised mRNA vaccines cut melanoma recurrence by 49%

Three-year follow-up results from the KEYNOTE-942 trial confirm that an individualised neoantigen therapy (mRNA-4157) combined with pembrolizumab reduced the risk of recurrence or death by 49% compared to pembrolizumab monotherapy in 157 patients with resected high-risk melanoma. The regimen also reduced distant metastasis risk by 62%. The approach uses sequencing algorithms to compare healthy tissue against biopsy samples, selecting up to 34 patient-specific mutations to encode into a synthetic mRNA strand.

Adjuvant cancer management has historically relied on standardized interventions with predictable failure rates. Here, computational sequence analysis isolates which tumor neoantigens display the highest predicted binding affinity to human leukocyte antigen class I molecules. Instead of waiting for a microscopic recurrence to register on an imaging scan, the biological defense is trained on day-zero genetic data.

Phase 3 confirmation remains necessary before broad clinical access, but the persistence of response across 36 months clarifies where preventive medicine is headed. When evaluating oncology monitoring options with your physician, ask directly how prospective genomic sequencing of your primary tissue might influence follow-up schedules or open access to biomarker-driven clinical trials.